Source-grounded facts extracted from AbbVie Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
AbbVie Inc. shareholders rejected The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair at the 2026-05-08 meeting.
“The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows: For Against Abstain Broker Non-Votes 515,626,009 787,253,970 6,198,473 239,399,581”
AbbVie Inc. shareholders rejected The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting at the 2026-05-08 meeting.
“The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows: For Against Abstain Broker Non-Votes 1,290,990,023 14,896,119 3,192,310 239,399,581”
AbbVie Inc. shareholders approved The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers at the 2026-05-08 meeting.
“The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, as follows: For Against Abstain Broker Non-Votes 1,228,615,745 69,336,359 11,126,348 239,399,581”
AbbVie Inc. shareholders approved The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026 at the 2026-05-08 meeting.
“The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026, as follows: For Against Abstain 1,522,575,012 23,766,564 2,136,457”
AbbVie Inc. shareholders approved The stockholders elected AbbVie’s Class II directors with terms expiring in 2029 at the 2026-05-08 meeting.
“The stockholders elected AbbVie’s Class II directors with terms expiring in 2029, as follows: Name For Against Abstain Broker Non-Votes Jennifer L. Davis 1,216,558,754 89,839,329 2,680,369 239,399,581 Melody B. Meyer 1,284,771,578 22,470,074 1,836,800 239,399,581 Robert A. Michael 1,221,224,370 85,865,852 1,988,230 239,399,581 Frederick H. Waddell 1,225,237,825 81,747,033 2,093,594 239,399,581”
AbbVie Inc. reported the first quarter ended March 31, 2026 results: revenue $15.002 billion, EPS $0.39. Guidance raised.
“Delivers First-Quarter Net Revenues of $15.002 Billion, an Increase of 12.4 Percent on a Reported Basis or 10.3 Percent on an Operational Basis”
AbbVie Inc. reported full-year ended December 31, 2026 results: EPS $13.96 - $14.16. Guidance lowered.
“AbbVie’s full-year 2026 adjusted diluted earnings per share guidance range, including the impact of first quarter 2026 acquired IPR&D and milestones expense, is $13.96 - $14.16.”
AbbVie Inc. reported quarter ended March 31, 2026 results: EPS $2.56 - $2.60. Guidance lowered.
“AbbVie’s first quarter 2026 adjusted diluted earnings per share guidance range, including the impact of first quarter 2026 acquired IPR&D and milestones expense, is $2.56 - $2.60.”
Glenn F. Tilton departed as Director at AbbVie Inc..
“The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.”
Richard A. Gonzalez departed as Director at AbbVie Inc..
“The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.”
Glenn F. Tilton departed as Director at AbbVie Inc..
“Glenn F. Tilton informed the Company of his decision to retire as a director, effective July 1, 2025.”
Richard A. Gonzalez departed as Chairman at AbbVie Inc..
“Mr. Gonzalez, who has served as Chairman since the Company’s formation in 2013, will retire from the Board, effective July 1, 2025.”
Robert A. Michael was elected as Chairman of the Board at AbbVie Inc..
“On February 13, 2025, the Board of Directors (the “Board”) of AbbVie Inc. (the “Company”) unanimously elected Robert A. Michael to succeed Richard A. Gonzalez as the Company’s Chairman, effective July 1, 2025.”
AbbVie Inc. announced a impairment with charges of approximately $3.5 billion affecting emraclidine intangible asset acquired as part of the acquisition of Cerevel Therapeutics Holdings, Inc..
“the estimated future cash flows for the product. Based on the revised cash flows, the company estimates a non-cash after-tax intangible asset impairment charge of approximately $3.5 billion. AbbVie continues to evaluate information with respect to the Cerevel-related clinical development programs and will monitor the remaining intangible assets of approximately $3.6”
AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on patent process at the 2024-05-03 meeting.
“The stockholders did not approve a stockholder proposal to issue an annual report on patent process, as follows: For Against Abstain Broker Non-Votes 315,426,248 941,651,498 17,953,817 245,929,517”
AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on lobbying at the 2024-05-03 meeting.
“The stockholders did not approve a stockholder proposal to issue an annual report on lobbying, as follows: For Against Abstain Broker Non-Votes 341,147,876 920,953,722 12,929,965 245,929,517”
AbbVie Inc. shareholders rejected Stockholder proposal to implement simple majority voting at the 2024-05-03 meeting.
“The stockholders did not approve a stockholder proposal to implement simple majority voting, as follows: For Against Abstain Broker Non-Votes 623,935,599 644,183,358 6,912,606 245,929,517”
AbbVie Inc. shareholders rejected Amendment of certificate of incorporation to eliminate supermajority voting at the 2024-05-03 meeting.
“The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows: For Against Abstain Broker Non-Votes 1,249,248,243 21,439,823 4,343,497 245,929,517”
AbbVie Inc. shareholders approved Advisory vote on frequency of future say on pay votes at the 2024-05-03 meeting.
“The stockholders approved, on an advisory basis, the frequency of the vote to approve the compensation of AbbVie’s named executive officers, as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 1,245,324,966 4,703,272 18,046,245 6,957,080 245,929,517”
AbbVie Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2024-05-03 meeting.
“The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, as follows: For Against Abstain Broker Non-Votes 1,169,920,693 96,635,849 8,475,021 245,929,517”
AbbVie Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for 2024 at the 2024-05-03 meeting.
“The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2024, as follows: For Against Abstain 1,492,584,834 25,439,349 2,936,897”
AbbVie Inc. shareholders approved Election of Class III directors with terms expiring in 2027 - Roxanne S. Austin, Richard A. Gonzalez, Susan E. Quaggin, Rebecca B. Roberts, Glenn F. Tilton at the 2024-05-03 meeting.
“The stockholders elected AbbVie’s Class III directors with terms expiring in 2027, as follows: Name For Against Abstain Broker Non-Votes Roxanne S. Austin 1,195,661,209 77,171,745 2,198,609 245,929,517 Richard A. Gonzalez 1,174,460,841 94,950,345 5,620,377 245,929,517 Susan E. Quaggin 1,264,358,441 8,524,362 2,148,760 245,929,517 Rebecca B. Roberts 1,223,837,505 48,797,905 2,396,153 245,929,517 Glenn F. Tilton 1,171,160,370 101,200,449 2,670,744 245,929,517”
Richard A. Gonzalez changed role as Executive Chairman of the Board at AbbVie Inc..
“Mr. Gonzalez will become Executive Chairman of the Board.”
Robert A. Michael was appointed as Chief Executive Officer at AbbVie Inc..
“selected Robert A. Michael to succeed Richard A. Gonzalez as AbbVie’s Chief Executive Officer (CEO), effective July 1, 2024”
AbbVie Inc. reported the first quarter ended March 31, 2024 results: revenue $12.310 Billion, EPS Diluted EPS of $0.77 on a GAAP Basis. Guidance raised.
“Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense • Delivers First-Quarter Net Revenues of $12.310 Billion, an Increase of 0.7 Percent on a Reported Basis and 1.6 Percent on an Operational Basis • First-Quarter Global Net Revenues from the Immunology Portfolio Were $5.371 Billion, a”
Robert A. Michael was appointed as Director at AbbVie Inc..
“The Board also appointed Mr. Michael as a member of the Board of Directors as a Class II director, effective July 1, 2024.”
Richard A. Gonzalez changed role as Executive Chairman at AbbVie Inc..
“Mr. Gonzalez, who has served as CEO since the company’s formation in 2013, will retire from the role of CEO and become Executive Chairman of the Board of Directors, effective July 1, 2024.”
AbbVie Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $14.301 billion, EPS $2.79. Guidance reaffirmed.
“These Results Include an Unfavorable Impact of $0.15 Per Share Related to Fourth-Quarter 2023 Acquired IPR&D and Milestones Expense • Delivers Fourth-Quarter Net Revenues of $14.301 Billion, a Decrease of 5.4 Percent • Announced Definitive Transaction Agreements to Acquire ImmunoGen and Cerevel Therapeutics, Strengthening AbbVie’s Oncology and Neuroscience”
AbbVie Inc. reported full-year ended December 31, 2023 results: EPS $11.04 - $11.08. Guidance reaffirmed.
“AbbVie’s full-year 2023 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2023 acquired IPR&D and milestones expense, is $11.04 - $11.08.”
AbbVie Inc. reported quarter ended December 31, 2023 results: EPS $2.72 - $2.76. Guidance reaffirmed.
“AbbVie’s fourth quarter 2023 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2023 acquired IPR&D and milestones expense, is $2.72 - $2.76.”
Susan Quaggin was appointed as Class III director at AbbVie Inc..
“and Susan Quaggin as a Class III director”
Jennifer Davis was appointed as Class II director at AbbVie Inc..
“appointed Jennifer Davis as a Class II director”
AbbVie Inc. updated its the third quarter of 2023 guidance (reaffirmed).
“Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2023 are expected to include acquired IPR&D and milestones expense of $66 million on a pre-tax basis, representing an unfavorable impact of $0.04 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2023 have not been finalized and are subject to our financial statement closing procedures.”
AbbVie Inc. reported the second quarter ended June 30, 2023 results: revenue $13.865 Billion, EPS $1.14. Guidance raised.
“PRESS RELEASE AbbVie Reports Second-Quarter 2023 Financial Results • Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Acquired IPR&D and Milestones Expense • Delivers Second-Quarter Net Revenues of $13.865 Billion, a Decrease of 4.9 Percent on a Reported Basis and 4.2 Percent on an Operational Basis • Second-Quarter Global Net Revenues from the Immunology Portfolio Were $6.813 Billion, a Decrease of 5.5 Percent on a Reported Basis, or 5.0 Percent on an Operational Basis; Global Humira Net Revenues Were $4.012 Billion; Global Skyrizi Net Revenues Were $1.883 Billion; Global Rinvoq Net Revenues Were $918 Million • Second-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.478 Billion, a Decrease of 10.4 Percent on a Reported Basis, or 9.8 Percent on an Operational Basis; Global Imbruvica Net”
AbbVie Inc. updated its second quarter of 2023 guidance (reaffirmed).
“Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2023 are expected to include acquired IPR&D and milestones expense of $280 million on a pre-tax basis, representing an unfavorable impact of $0.15 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2023 have not been finalized and are subject to our financial statement closing procedures.”
Robert A. Michael was appointed as President and Chief Operating Officer at AbbVie Inc..
“Effective June 29, 2023, Robert A. Michael has been appointed President and Chief Operating Officer.”
AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on patent process at the 2023-05-05 meeting.
“(8) The stockholders did not approve a stockholder proposal to issue an annual report on patent process, as follows: For Against Abstain Broker Non-Votes 363,777,601 867,061,281 25,751,703 251,363,568”
AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on lobbying at the 2023-05-05 meeting.
“(7) The stockholders did not approve a stockholder proposal to issue an annual report on lobbying, as follows: For Against Abstain Broker Non-Votes 448,957,091 787,145,991 20,487,503 251,363,568”
AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on political spending at the 2023-05-05 meeting.
“(6) The stockholders did not approve a stockholder proposal to issue an annual report on political spending, as follows: For Against Abstain Broker Non-Votes 187,829,409 1,052,110,624 16,650,552 251,363,568”
AbbVie Inc. shareholders approved Stockholder proposal to implement simple majority voting at the 2023-05-05 meeting.
“(5) The stockholders approved a stockholder proposal to implement simple majority voting, as follows: For Against Abstain Broker Non-Votes 668,497,335 581,300,391 6,792,859 251,363,568”
AbbVie Inc. shareholders rejected Amendment of certificate of incorporation to eliminate supermajority voting at the 2023-05-05 meeting.
“(4) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows: For Against Abstain Broker Non-Votes 1,241,106,832 11,289,016 4,194,737 251,363,568”
AbbVie Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2023-05-05 meeting.
“(3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2023 annual meeting, as follows: For Against Abstain Broker Non-Votes 1,137,389,680 109,281,658 9,919,247 251,363,568”
AbbVie Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for 2023 at the 2023-05-05 meeting.
“(2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2023, as follows: For Against Abstain 1,486,053,290 18,676,821 3,224,042”
AbbVie Inc. shareholders approved Election of Class II Directors at the 2023-05-05 meeting.
“(1) The stockholders elected AbbVie’s Class II Directors with terms expiring in 2026, as follows: Name For Against Broker Non-Votes Robert J. Alpern 1,142,062,843 20,689,813 251,363,568 Melody B. Meyer 1,247,333,998 4,243,832 251,363,568 Frederick H. Waddell 1,208,836,612 14,319,844 251,363,568”
AbbVie Inc. reported the first quarter ended March 31, 2023 results: revenue $12.225 Billion, EPS $0.13. Guidance raised.
“AbbVie Reports First-Quarter 2023 Financial Results • Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share related to Acquired IPR&D and Milestones Expense • Delivers First-Quarter Net Revenues of $12.225 Billion, a Decrease of 9.7 Percent on a Reported Basis and 8.3 Percent on an Operational Basis”
AbbVie Inc. amended revolving credit of $5.0 billion with JPMorgan Chase Bank, N.A. maturing March 28, 2028.
“(i) increases the unsecured revolving credit facility commitments from $4.0 billion to $5.0 billion and (ii) extends the maturity date of the facility from August 27, 2024 to March 28, 2028.”
AbbVie Inc. entered into Second Amended and Restated Revolving Credit Agreement with JPMorgan Chase Bank, N.A. valued at $5.0 billion (effective 2023-03-28).
“On March 28, 2023 (the “Effective Date”), AbbVie Inc. (“AbbVie”) entered into an amended and restated revolving credit agreement (the “Second Amended and Restated Revolving Credit Agreement”) among AbbVie, as borrower, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as administrative agent”
AbbVie Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
“On February 9, 2023, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2022.”
AbbVie Inc. reported the full-year ended December 31, 2022 results: EPS $13.70 - $13.74. Guidance reaffirmed.
“AbbVie’s full-year 2022 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2022 acquired IPR&D and milestones expense, is $13.70 - $13.74.”
AbbVie Inc. reported the quarter ended December 31, 2022 results: EPS $3.51 - $3.55. Guidance reaffirmed.
“AbbVie’s fourth quarter 2022 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2022 acquired IPR&D and milestones expense, is $3.51 - $3.55.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.